NCT03175432View on ClinicalTrials.gov

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 15, 2017

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
BRAF V600 Wild TypeClinical Stage IV Cutaneous Melanoma AJCC v8Intracranial MelanomaMetastatic Malignant Neoplasm in the BrainMetastatic MelanomaPathologic Stage IV Cutaneous Melanoma AJCC v8Refractory Melanoma
Interventions
DRUG

Atezolizumab

Given IV

BIOLOGICAL

Bevacizumab

Given IV

DRUG

Cobimetinib

Given PO

PROCEDURE

Quality-of-Life Assessment

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER